Bibliography
- CARACENI A, MARTINI C, ZECCA E et al.: Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat. Med. (2004) 18:177-183.
- PORTENOY RK, BENNETT DS, RAUCK R et al.: Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J. Pain (2006) 7:583-591.
- BENNETT D, BURTON A, FISHMAN S et al.: Consensus panel recommendations for the assessment and management of breakthrough pain. Part 1. Assessment. Pharm. Ther. (2005) 30:296-301.
- PORTENOY RK, HAGEN NA: Breakthrough pain: definition, prevalence and characteristics. Pain (1990) 41:273-281.
- PORTENOY RK, PAYNE D, JACOBSEN P: Breakthrough pain: characteristics and impact in patients with cancer pain. Pain (1999) 81:129-134.
- MERCADANTE S, MADDALONI S, ROCCELLA S, SALVAGGIO L: Predictive factors in advanced cancer pain treated only by analgesics. Pain (1992) 50:151-155.
- MERCADANTE S, ARMATA M, SALVAGGIO L: Pain characteristics of advanced lung cancer patients referred to a palliative care service. Pain (1994) 59:141-145.
- FORTNER BV, OKON TA, PORTENOY RK: A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J. Pain (2002) 3:38-44.
- FORTNER BV, DEMARCO G, IRVING G et al.: Description and predictors of direct and indirect costs of pain reported by cancer patients. J. Pain Symptom Manage. (2003) 25:9-18.
- BENNETT D, BURTON AW, FISHMAN S et al.: Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2. Management. Pharm. Ther. (2005) 30:354-361.
- FINE PG, MARCUS M, DE BOER AJ, VAN DER OORD B: An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain. Pain (1991) 45:149-153.
- FARRAR JT, CLEARY J, RAUCK R, BUSCH M, NORDBROCK E: Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J. Natl. Cancer Inst. (1998) 90:611-616.
- MYSTAKIDOU K, KATSOUDA E, PARPA E, TSIATAS ML, VLAHOS L: Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics. Am. J. Hosp. Palliat. Care (2005) 22:228-232.
- GHEE S, CUNNINGHAM J, ROME J, REID K: Dental disease and the use of oral transmucosal fentanyl – a case report. 23rd Annual Meeting of the American Academy of Pain Medicine. New Orleans, LA, USA (7 – 10 February 2007).
- STANLEY TH: Fentanyl. J. Pain Symptom Manage. (2005) 29(5 Suppl.):S67-S71.
- DURFEE S, MESSINA J, KHANKARI R: Fentanyl effervescent buccal tablets. Am. J. Drug Deliv. (2006) 4:1-5.
- STREISAND JB, ZHANG J, NIU S, MCJAMES S, NATTE R, PACE NL: Buccal absorption of fentanyl is pH-dependent in dogs. Anesthesiology (1995) 82:759-764.
- DARWISH M, KIRBY M, ROBERTSON P Jr, HELLRIEGEL E, JIANG JG: Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers. J. Clin. Pharmacol. (2007) 47:56-63.
- MATHER LE: Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin. Pharmacokinet. (1983) 8:422-446.
- HILL HF, CHAPMAN CR, SAEGER LS et al.: Steady-state infusions of opioids in human. II. Concentration-effect relationships and therapeutic margins. Pain (1990) 43:69-79.
- DARWISH M, KIRBY M, JIANG JG: Effect of buccal dwell time on the pharmacokinetic profile of fentanyl buccal tablet. Expert Opin. Pharmacother. (2007) 8:2011-2016.
- DARWISH M, KIRBY M, ROBERTSON P, TRACEWELL W, JIANG JG: Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J. Clin. Pharmacol. (2007) 47:343-350.
- DARWISH M, KIRBY M, ROBERTSON P, TRACEWELL W, JIANG JG: Absorption of fentanyl from fentanyl buccal tablet (FBT) in cancer patients with or without oral mucositis – a pilot study. Clin. Drug Investig. (2007) 27:605-611.
- PORTENOY RK, TAYLOR D, MESSINA J, TREMMEL L: A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin. J. Pain (2006) 22:805-811.
- SLATKIN NE, XIE F, MESSINA J SEGAL TJ: Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J. Support. Oncol. (2007) 5:327-334.
- SIMPSON DM, MESSINA J, XIE F, HALE M: Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin. Ther. (2007) 29:588-601.
- PORTENOY RK, MESSINA J, XIE F, PEPPIN J: Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study. Curr. Med. Res. Opin. (2007) 23:223-233.
- NALAMACHU S, XIE F, MESSINA J: Mood, functioning, and quality of life in opioid-tolerant patients with noncancer chronic pain and breakthrough pain: effect of fentanyl buccal tablet. J. Pain (2007) 8:S43.
- WEBSTER LR: Fentanyl buccal tablets. Expert Opin. Investig. Drugs (2006) 15:1469-1473.
- TAYLOR DR, MESSINA J, XIE F, WEBSTER L: Multi-study analysis of patients' preference for fentanyl buccal tablet (FBT) in the management of breakthrough pain. 26th Annual Scientific Meeting of the American Pain Society. Washington, DC, USA (2 – 5 May 2007).
Websites
- Cephalon Inc. Prescribing information for Fentora. http://www.cephalon.com/newsroom/assets/FENTORA_Prescribing_Information.pdf. June 2006 [Accessed on 23 July 2007].
- FDA safety information and adverse event reporting program. http://www.fda.gov/Medwatch/SAFETY/2007/safety07.htm#Fentora [Accessed on 27 September 2007].